Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: Covid rebound after taking paxlovid; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Covid rebound after taking paxlovid) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient was taking other medications/products within 2 weeks of starting COVID-19 treatment.  Concurrent medical conditions included Asthma and Allergy (Drug name not reported (Patient do not think so)).   On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Covid rebound after taking paxlovid). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 17-May-2022 to 21-May-2022 for COVID-19 treatment, at a dose of 1 dosage form. At the time of the report, COVID-19 (Covid rebound after taking paxlovid) outcome was unknown.            No concomitant medication was provided.  Device Date : 28-May-2022.  Company comment: This is a spontaneous case concerning a 74-year-old, female patient with no relevant medical history and with vaccine history of receiving first and second dose of mRNA-1273 vaccine with appropriate dosage interval of 28 days. The patient experienced the unexpected non-serious AESI event of Covid-19. The event occurred approximately 5 to 6 months after the third dose of mRNA-1273 vaccine administration. Allegedly the event was described as, approximately 179 days after the third dose of mRNA-1273 vaccine administration, patient took Nirmatrelvir + Ritonavir (Paxlovid) as treatment for Covid-19. Approximately 7 days after the last dose of Paxlovid, patient experienced rebound Covid. No other information surrounding the event was reported. The outcome of the event was reported as unknown from the time of last observation. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 74-year-old, female patient with no relevant medical history and with vaccine history of receiving first and second dose of mRNA-1273 vaccine with appropriate dosage interval of 28 days. The patient experienced the unexpected non-serious AESI event of Covid-19. The event occurred approximately 5 to 6 months after the third dose of mRNA-1273 vaccine administration. Allegedly the event was described as, approximately 179 days after the third dose of mRNA-1273 vaccine administration, patient took Nirmatrelvir + Ritonavir (Paxlovid) as treatment for Covid-19. Approximately 7 days after the last dose of Paxlovid, patient experienced rebound Covid. No other information surrounding the event was reported. The outcome of the event was reported as unknown from the time of last observation. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.